Rituximab for steroid-dependent nephrotic syndrome.
Minimal change disease (MCD) is characterized by marked sensitivity to glucocorticoid therapy. However, in 40 - 50% of all cases the disease presents with frequent relapses and needs repeated courses of steroids as well as additional immunosuppressive therapy including azathioprine, cyclophosphamide or cyclosporine. Because such regimens are associated with significant toxicity, the therapeutic challenge of this disease is to identify the treatment with the highest probability of producing a sustained remission with the lowest risk of toxicity. There is increasing evidence that rituximab may play an important role in the treatment of idiopathic nephrotic syndrome. Here, we present an adult patient with steroid-sensitive but high-dose steroid-dependent MCD beginning in childhood with a heavy history of multiple immunosuppressive therapy that was brought into 1 year sustained remission of proteinuria with two infusions of rituximab (375 mg/m2).
Beco
A
A
Nephrology Research and Development Unit, Faculty of Medicine, University of Porto and Hospital de S. Joao EPE, Alameda Prof. Hernani Monteiro, Porto, Portugal. coentrao@med.up.pt
Castro-Ferreira
I
I
Coentrao
L
L
Neto
R
R
Sampaio
S
S
Pestana
M
M
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use*; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D011239:Prednisolone